4.5 Article

High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer

Journal

BREAST
Volume 30, Issue -, Pages 39-46

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2016.08.014

Keywords

LDHA; AMPK; Breast cancer; Prognosis; Tumor metabolism

Funding

  1. National Natural Science Foundation of China [81472575, 81472469, 81272514]
  2. Science and Technology Planning Projects of Guangdong and Guangzhou [2013B060300009, 2015B020211002, 2015B090901050, 2014A020212079]

Ask authors/readers for more resources

Objectives: The purpose of this study was to investigate the potential correlation between lactate dehydrogenase A (LDHA) and AMP-activated protein kinase (AMPK) and their clinicopathologic significance in breast cancer. Materials and Methods: Western blot and qRT-PCR were used to detect the expression levels of LDHA and AMPK in eight breast cancer lines and eight breast cancer tissues. In addition, LDHA and AMPK were detected by immunohistochemistry (IHC) using breast cancer tissue microarrays (TMAs) of 112 patients. The association between LDHA and AMPK expression levels was statistically analyzed. So were the prognostic roles and clinicopathologic significances in breast cancer. Results: The expression levels of LDHA and. AMPK were relatively higher in triple-negative breast cancer (TNBC) cell lines than in non-triple-negative breast cancer (NTNBC) cell lines. LDHA and AMPK were also further up-regulated in TNBC tissues than in NTNBC tissues. Correlation analysis showed a positive correlation between LDHA and AMPK expression levels. Expression of LDHA and AMPK were significantly correlated with TNM stage, distant metastasis, Ki67 status and survival outcomes of patients. Patients with both positive expression of LDHA and AMPK showed shorter overall survival (OS) and disease-free survival (DFS). Conclusions: These findings improve our understanding of the expression pattern of LDHA and AMPK in breast cancer and clarify the role of LDHA and AMPK as promising prognostic biomarkers for breast cancer. (C) 2016 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available